TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of either sex between 12 and 70 years of age.~* Patients with documented clinical history of SAR, for at least 2 years prior to the study inclusion.~* Positive skin prick test for at least one of the seasonal allergen specific of the geographical area.~* A previous positive Prick test, or a positive IgE Test (RAST) may also be accepted for inclusion, if performed within 12 months prior to the inclusion.~Exclusion Criteria:~* Patients who have non-allergic rhinitis (vasomotor, infectious, drug-induced, etc.).~* Negative skin prick test (as defined in point 6.1.1.).~* Patients with nasal polyps or a significant deviation of the nasal septum as judged by the investigator as well as nasal intervention in the previous 6 months. Any other nasal illness that can interfere with the aim of the study.~* Patients who have acute or chronic sinusitis as judged by the investigator.~* Patients who have received anti-allergy immunotherapy in the previous two years or are still receiving this kind of therapy.~* Patients who are taking or have taken specified medications prior to randomisation in the study and have not complied with the specified washout period

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Bilastine
- B (Type: ACTIVE_COMPARATOR): Cetirizine
- C (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a history of moderate to severe plaque psoriasis for at least 6 months prior to Visit 1;~* Subjects with moderate to severe plaque psoriasis covering ≥10% body surface area (BSA), with a psoriasis area and severity index (PASI) ≥12 and static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2~Exclusion Criteria:~* History of discontinuation of biologic therapies (including marketed and investigational drugs) directly targeting Interleukin (IL)-17A, IL-17A/F, IL-17 receptor A, IL-12/IL-23p40 or IL-23p19 due to lack of efficacy, according to the Investigator's judgment;~* Prior exposure to retinoid-related orphan receptor (ROR)-γ inhibitors;~* Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions (e.g., clinically-significant eczema or severe acne) at Visit 1;~* History or presence of itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin within 12 months prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- JTE-451 Dose 1 (Type: EXPERIMENTAL): JTE-451 Tablets Dose 1 daily for 16 weeks.
- JTE-451 Dose 2 (Type: EXPERIMENTAL): JTE-451 Tablets Dose 2 daily for 16 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Tablets daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Parkinson's Disease of Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of primary Parkinson's disease~* In a Hoehn and Yahr stage less than stage III~* Disease duration is less than 5 years~* Not likely to require dopaminergic therapy within 6 months~Exclusion Criteria:~* Use of any PD medication within 60 days prior to the beginning the study, including levodopa, direct dopamine agonists, amantadine, Rasagiline (Azilect), Selegiline (Eldepryl), Artane (trihexyphenidyl).~* Duration of previous use of medications for PD that exceeds 90 days~* Expected to require dopaminergic therapy in the next 6 months~* Poorly controlled or unstable cardiovascular disease~* Uncontrolled hypertension~* Hypo- or hyperthyroidism, abnormal liver function, abnormal renal function~* Mild cognitive impairment (Montreal Cognitive Assessment score\<26/30)~* Depression that precludes ability to exercise (Beck depression score\>13)~* Disorders that interfere with ability to perform endurance exercises~* Regular participation in vigorous endurance exercise~* Evidence of serious arrhythmias or ischemic heart disease~* Any clinically significant medical condition, psychiatric condition, drug or alcohol abuse, or laboratory abnormality that would, in the judgment of the investigators, interfere with the ability to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: SHAM_COMPARATOR): Wait listed to moderate or vigorous exercise after 6 months of no exercise.
- Vigorous Exercise (Type: EXPERIMENTAL): Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
- Moderate Exercise (Type: EXPERIMENTAL): Endurance exercise at 60-65% HR max, 4x/wk for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.~* Measurable disease according to RECIST version 1.1.~* Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs.~* Prior radiotherapy is allowed~* Patients with controlled asymptomatic central nervous system involvement are allowed.~* Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.~* Adult patients age 18 years or older.~* Life expectancy of at least 3 months.~Key Exclusion Criteria:~* Current participation in another therapeutic clinical trial.~* Prior treatment with entrectinib.~* History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \> 450 milliseconds).~* History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome).~* Known active infections (bacterial, fungal, viral including HIV positivity).~* Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.~* Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.~* Peripheral neuropathy ≥ Grade 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entrectinib (RXDX-101) (Type: EXPERIMENTAL): Oral entrectinib (RXDX-101)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy females, who were sexually active and at risk of pregnancy were eligible to participate in this study provided that they had regular menses occurring every 25 to 35 days (except for those women using medroxyprogesterone acetate)~* women who were using one of the following methods of contraception as their primary method in the 3 months prior to admission: oral contraceptive, intrauterine device, medroxyprogesterone acetate injection, double-barrier method consisting of condoms and spermicidal foam or gel, or a diaphragm and spermicidal foam or gel~* study participants had to have a normal Pap smear within the previous 12 months~* a negative urine pregnancy test at admission~* have a systolic/diastolic blood pressure \<= 140/90 mm Hg~* be within 35% of acceptable body mass index (upper limit of 32.4)~* be willing to switch their current method of contraception~* and agree not to use any other steroid hormonal therapy other than topical corticosteroids or inhaled corticosteroids for asthma, during the course of the study.~Exclusion Criteria:~* History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy, e.g., deep vein thrombophlebitis, thromboembolic disorders, cerebral vascular or coronary artery disease, etc.~* Additionally, participants who were menopausal~* had skin conditions resulting in oily, irritated or damaged skin at all potential application sites~* Had a history or presence of dermal hypersensitivity~* The presently used contraceptive method were any of condoms alone, abstinence, withdrawal, or a rhythm method~* Had received medroxyprogesterone acetate injection \<=12 weeks prior to enrolment~* had a history of alcohol or substance abuse within 12 months of enrolment~* had received any experimental drug or device within 30 days of enrolment~* Had used barbiturates, antiepileptics, rifampin, griseofulvin, or other hepatic enzyme inducing drugs within 30 days of enrolment~* Chronic systemic antibiotic use~* Had an uncontrolled thyroid disorder~* Were smokers over the age of 35~* Had Pap smear evidence of atypical squamous cells or adenocarcinoma or other malignancy~* Had a desire to conceive in the subsequent 9 months of enrolment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes.~* At least 30 years old and less than 80 years old.~* Using oral agents without insulin for 30 days prior ot study.~* Willing to start insulin injections using a pen device.~* Keep a patient diary.~Exclusion Criteria:~* Undergoing therapy for cancers.~* History of renal transplant or receiving renal dialysis.~* Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.~* Women who are breastfeeding.~* Have been treated with a drug within the last 30 days that has not received regulatory approval.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between 19 and 75 years old based on the date of written agreement~* Those who are diagnosed with acute or chronic gastritis with at least one erosion observed on upper gastrointestinal endoscopy~* Those who had experienced one or more subjective symptoms of gastritis~Exclusion Criteria:~* Those who have had surgery to reduce gastric acid secretion, or gastric or esophageal surgery~* Those with history of clinically significant hepatic, renal, neurologic, pulmonary, endocrine, hematologic, cardiovascular or genitourinary disease that could affect the study results

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DWP14012 X mg QD (Type: EXPERIMENTAL): * Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo~* Evening: 1 tablet of DWP14012 Y mg placebo
- DWP14012 Y mg BID (Type: EXPERIMENTAL): * Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg~* Evening: 1 tablet of DWP14012 Y mg
- placebo (Type: PLACEBO_COMPARATOR): * Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo~* Evening: 1 tablet of DWP14012 Y mg placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women with polycystic ovaries~Exclusion Criteria:~* women with other causes of infertility

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- preparation F12 sildenafil in-situ gel group (Type: EXPERIMENTAL): women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
- preparation F2 sildenafil in-situ gel group (Type: ACTIVE_COMPARATOR): women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
- placebo gel group (Type: PLACEBO_COMPARATOR): women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:~  * Smoking history of at least 10 pack-years~ * Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value~ * Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria:~* Patients who have received systemic corticosteroids and/or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg and tiotropium 18 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Tiotropium 18 μg (Type: ACTIVE_COMPARATOR): Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria~* Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55 years of age (Part 1)~* Male subjects, female subjects of non-childbearing potential, female subjects of childbearing potential with documented bilateral tubal ligation (tubes tied) or bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or reduction/loss of smell (Part 2)~* Male or female subjects between the ages of 18 and 75 years, inclusive with moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study (Part 3)~Exclusion Criteria:~* Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.), positive urine drug test, fever within 7 days of dosing, active infections within 28 days of dosing (Part 1 and 2 and 3)~* History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part 2)~* Exposure to live or attenuated vaccines, have skin conditions other than Atopic Dermatitis, use of JAK inhibitors and biologics (Part 3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 10 mg of PF-06817024 or placebo
- Cohort 2 (Type: EXPERIMENTAL): 30 mg of PF-06817024 or placebo
- Cohort 3 (Type: EXPERIMENTAL): 100 mg of PF-06817024 or placebo
- Cohort 4 (Type: EXPERIMENTAL): 300 mg of PF-06817024 or placebo
- Cohort 5 (Type: EXPERIMENTAL): 1000 mg of PF-06817024 or placebo
- Cohort 6 (Type: EXPERIMENTAL): 2000 mg of PF-06817024 or placebo
- Cohort 7 (Type: EXPERIMENTAL): 30 mg subcutaneous dose of PF-06817024 or placebo
- Cohort 8 (Type: EXPERIMENTAL): 300 mg of PF-06817024 or placebo
- Cohort 9 (Type: EXPERIMENTAL): IV dose to be determined of PF-06817024 or placebo
- Cohort 10 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 11 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 12 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 13 (Type: EXPERIMENTAL): PF-06817024 or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Japanese participant diagnosed with compensated CHC GT 1~* Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease.~* IFN treatment naive~* No evidence of cirrhosis~Exclusion criteria:~* Co-infection with human immunodeficiency virus (HIV)~* Positive hepatitis B surface antigen or other evidence of active hepatitis B infection~* Any other condition that is contraindicated or for which caution is required for treatment with peg-IFN or RBV~* Any condition or pre-study laboratory abnormality, or history of any illness, that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs, peg-IFN and RBV, to the participant.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 12 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
- Vaniprevir 24 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
- Control Arm (Type: ACTIVE_COMPARATOR): Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete